Status:
WITHDRAWN
Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding Due to Trauma
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Acquired Bleeding Disorder
Trauma
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
This trial is conducted in the United States of America (USA). The purpose of this study is to evaluate the treatment of Recombinant Faction VIIa in Patients with Severe Bleeding Due to Trauma Please...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Trauma injury (blunt and/or penetrating) with evidence of active torso hemorrhage refectory to standard treatment
Exclusion
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2007
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00323570
Start Date
May 1 2006
End Date
June 1 2007
Last Update
June 27 2012
Active Locations (42)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Clinical Trial Call Center
Phoenix, Arizona, United States, 85008
2
Novo Nordisk Clinical Trial Call Center
Los Angeles, California, United States, 90033
3
Novo Nordisk Clinical Trial Call Center
Sacramento, California, United States, 95817
4
Novo Nordisk Clinical Trial Call Center
Colorado Springs, Colorado, United States, 80909